Novo Nordisk's Wegovy Cuts COVID-19 Deaths by 33%, Lowers Heart Failure Risks

Aug 30, 2024, 12:00 PM

Recent studies have shown that Novo Nordisk's obesity drug Wegovy, which contains the active ingredient semaglutide, significantly reduces the risk of severe complications and mortality in patients with heart failure and COVID-19. A new analysis found that Wegovy cut the chances of patients dying from COVID-19 by roughly a third compared to placebo, with people taking the drug being 33% less likely to die of COVID-19. Additionally, semaglutide was shown to reduce the risk of heart failure events and cardiovascular death by up to 29% in diabetic patients. These findings were supported by a pooled analysis of four trials, which demonstrated a reduction in emergency hospitalization visits and a composite endpoint including cardiovascular death. The research highlights the potential of Wegovy to bolster the immune system and improve outcomes in patients with obesity and related health conditions.